Cornerstone Pharmaceuticals, Inc.

Cornerstone Pharmaceuticals, Inc.

Specialty Pharma
BioNJ Member Type: Core

Cornerstone is engaged in the discovery and development of innovative and novel cancer therapeutics taking advantage of the unique features of cancer metabolism. Cornerstone is developing two distinct technologies, AEMD (“Altered Energy Metabolism Directed”) and Emulsiphan. The AEMD technology platform generates molecules that selectively target and perturb essential processes in cancer cell energy metabolism, resulting in cell death. The Emulsiphan technology is based on a nanoemulsion based drug delivery platform designed to deliver non-specific chemotherapeutic drugs specifically into the cancer cell. Cornerstone is current in clinical development with its lead AEMD platform, CPI-613.

Special Offers:
Mention BioNJ and receive a 20% discount. One-time offer available to new clients only.


One Duncan Drive
Cranbury, NJ 08512